Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up

Nektar's (NKTR) earnings and revenues beat estimates in Q3. The company also raises its revenue guidance for the same period.

    Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus

    Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.

      Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View

      Horizon Pharma (HZNP) Q3 results were driven by growth from the orphan and rheumatology business.

        Mylan (MYL) Misses on Earnings and Sales Estimates in Q3

        Mylan (MYL) missed both earnings and sales estimates in the third quarter of 2017 as EpiPen sales continue to decline further.

          ImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up

          ImmunoGen (IMGN) reports wider-than-expected loss in Q3. Revenues also lag expectations considerably.

            Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3

            Immune Design (IMDZ) reported narrower-than-expected loss and missed sales estimates in the third-quarter 2017.

              Exelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx Sales

              Exelixis (EXEL) beat both earnings and sales estimates in the third quarter fueled by strong demand for Cabometyx for RCC.

                Is a Beat in the Cards for Mylan (MYL) This Earnings Season?

                Mylan N.V. (MYL) is likely to beat results when it reports third-quarter results next week driven by newly launched generics.

                  What's in the Cards for Prothena (PRTA) in Q3 Earnings?

                  Investors focus should remain on pipeline updates when Prothena Corporation (PRTA) reports third-quarter results as it has no approved product in its portfolio.

                    Is a Beat in the Cards for ImmunoGen (IMGN) in Q3 Earnings?

                    ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the company's third-quarter results.

                      What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?

                      Immune Design (IMDZ) will remain focused on the development of its key pipeline candidate's CMB305 and G100 in the third quarter of 2017.

                        What's in the Offing for Exelixis (EXEL) in Q3 Earnings?

                        Exelixis, Inc. (EXEL) received a major boost with the FDA's approval of Cabometyx tablets and we expect investor focus on the drug's uptake when it reports third-quarter results.

                          Seattle Genetics (SGEN) Loss Narrows in Q3, Revenues Beat

                          Seattle Genetics (SGEN) reported narrower-than-estimated loss in the third quarter. Moreover, including a warrant exercise it turned profitable. The shares were up in response.

                            What to Expect From Epizyme (EPZM) This Earnings Season?

                            Epizyme (EPZM) is a development-stage company, with no approved products in its portfolio. Hence, investor focus is expected to remain on the company's pipeline updates and mainly on its lead candidate, tazemetostat.

                              Mark Vickery headshot

                              Top Research Reports for Lockheed Martin, 3M & T-Mobile

                              Today's Research Daily features new research reports on 16 major stocks, including Lockheed Martin (LMT), 3M (MMM), and T-Mobile (TMUS).

                                Can AbbVie (ABBV) Spring a Surprise this Earnings Season?

                                Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q3.

                                  Novartis (NVS) Q3 Earnings & Sales Top on New Drugs Strength

                                  Novartis AG (NVS) third-quarter results topped estimates driven by strong performance of Cosentyx and Entresto.

                                    Key Predictions for Q3 Earnings Reports of LLY, BIIB, NVS

                                    The pharma/biotech industry has seen a solid start to the Q3 earnings season as evident from J&J's solid results. Let's see if the other leading players -- Lilly, Biogen and Novartis -- follow suit.

                                      Roche (RHHBY) Reports Sales Numbers for First 9 Months

                                      Roche Holding AG's (RHHBY) reported sales of CHF39.4 billion in the first nine months of 2017, up 5% from the year-ago period.

                                        BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer

                                        BioLineRx (BLRX) and partner Genentech initiate a phase Ib/II study to evaluate the company's lead pipeline candidate, BL-8040, in combination with Tecentriq for treating gastric cancer.

                                          Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?

                                          At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.

                                            ImmunoGen to Push Leukemia Candidate into Phase I Trial

                                            ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.

                                              Inovio Initiates Bladder Cancer Study With Roche's Tecentriq

                                              Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.

                                                FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx

                                                Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.

                                                  Swarup Gupta headshot

                                                  Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion

                                                  Foreign markets remain undeterred by discouraging events, notching up weekly gains.